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ABSTRACT 
Walking treatment is recommended for improving intermittent claudication (IC), a debilitating 
symptom of leg pain caused by peripheral arterial disease. However, centre-based exercise 
programmes offered in a community or hospital setting are often not implemented or adhered to.  
We developed a home-delivered behaviour-change intervention, Motivating Structured walking 
Activity in Intermittent Claudication (MOSAIC), to increase walking in people with IC.  A feasibility 
randomised controlled trial with nested qualitative interviews involving a subsample of trial 
participants was conducted. Feasibility criteria evaluated a) participant recruitment and retention; b) 
suitability of proposed outcome measures; and c) acceptability and adherence to the intervention 
and trial. Participants (adults ≥18 years diagnosed with IC identified from vascular outpatient clinics) 
were randomised 1:1 to receive MOSAIC treatment (two 60-minute home-based sessions and two 
20-minute booster telephone calls incorporating behaviour-change techniques) or an attention-
control comparison. Outcomes (baseline and 16-week follow-up) included: the 6-Minute Walk 
Distance (metres), pedometer-assessed daily walking activity (steps/day), health related quality of 
life, physical functioning, and beliefs about walking treatment, peripheral arterial disease, and self-
regulatory processes. 24 Participants (mean age 66.8 ±9.4 years, 79% male) were included. 
Feasibility criteria achieved were: recruitment rate (25%), participant retention (92%), and 
adherence to assigned treatment or attention-control sessions (71%). Missing data rates were <10% 
for all outcomes except baseline daily walking activity (36%). The trial protocol and interventions 
were acceptable to participants and the clinician. In conclusion, the MOSAIC trial was feasible to 
conduct, with the exception of high missing pedometer data.  The intervention is an acceptable 
approach to facilitate walking among people with IC.  
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HIGHLIGHTS 
• A home walking programme for intermittent claudication was feasible to deliver 
• The 6-Minute Walk Distance is a feasible and clinically relevant outcome 
• Strategies to reduce missing pedometer data should be employed  
• Patients reported acceptability and therapeutic alliance following the programme 
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A randomised controlled feasibility trial of a home-based walking behaviour-change intervention 
for people with intermittent claudication 
INTRODUCTION 
Peripheral arterial disease is a vascular condition characterised by atherosclerotic narrowing 
or occlusion in the arteries of the lower limb, which affects up to 20% of older adults [1].  A 
common symptom of peripheral arterial disease is intermittent claudication, a debilitating 
ischaemic leg pain that occurs during walking. Intermittent claudication contributes to 
reduced mobility, low quality of life, and increased cardiovascular risk [2, 3], and it is therefore 
an important but complex condition to manage. 
Guidelines recommend walking as first-line treatment for all patients presenting with 
intermittent claudication [4], comprising 30 minutes of supervised exercise on at least 3 days 
per week, at an intensity eliciting moderate symptoms within 3-5 minutes. However, 
recommendations are often not implemented due to the costs and expertise required to 
initiate and deliver a centre-based programme, such as those offered in a community or 
hospital setting [5]. Instead, patients often receive simple “go home and walk” advice from a 
clinician, which is varied and ineffective [6, 7]. Home-based exercise programmes offer 
structure and supervision beyond simple walking advice and may overcome barriers related 
to travel and accessibility [8], particularly among patients with limited mobility. In addition, 
most people with intermittent claudication report a preference for home-delivered exercise 
[9]. However, evidence from systematic reviews is limited and inconsistent, and suggests 
home-based exercise is not effective [10]. One reason for this may be that few such 
programmes have incorporated theory-based strategies to change behaviour and enable 
uptake and long-term walking adherence required to sustain benefits [11, 12].  
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Essential conditions for individual behaviour change include positive and accurate beliefs 
about peripheral arterial disease (e.g., illness perceptions defined by the Common Sense 
Model of Illness Representations [13]) and walking  treatment (e.g., beliefs defined by the 
Theory of Planned Behaviour  [14]). Positive beliefs about walking defined by the Theory of 
Planned Behaviour have been associated with greater motivation to walk, self-reported 
walking activity, and walking capacity in people with intermittent claudication [15, 16]. In 
addition, illness perceptions including beliefs about the controllability and cause of PAD, and 
patients’ understanding of their PAD, have been associated with greater walking capacity 
[16]. Therefore, the Common Sense Model of Illness Representations and Theory of Planned 
Behaviour provide useful models to underpin a walking behaviour-change intervention for 
people with intermittent claudication. 
Behaviour-change techniques are strategies which help to translate theoretical determinants 
into practice [17]. Examples of behaviour-change techniques include simple tasks such as 
setting walking goals, learned skills including action planning (planning when, where and how 
to walk), or complex approaches delivered by qualified clinicians including motivational 
interviewing (exploring ways to minimise resistance and ambivalence toward increasing 
walking). Home-delivered exercise programmes incorporating behaviour-change techniques 
are recommended for people with intermittent claudication [11] and could contribute to the 
development and evaluation of robust and feasible walking programmes.  
Therefore, a brief, structured, home-delivered walking behaviour-change intervention, 
MOtivating Structured walking Activity in Intermittent Claudication (MOSAIC), was 
systematically developed [18]. MOSAIC builds on previous research [19], and has been refined 
based on developmental work [12, 20] and stakeholder feedback, including consultation with 
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PAD patients and healthcare professionals to improve the potential for implementation. The 
aim of this study was to evaluate the feasibility of a two-arm, single-blind, randomised 
controlled trial comparing MOSAIC to an attention-control consistent with Consolidated 
Standards of Reporting Trials (CONSORT) guidelines [21], which is an evidence-based, 
minimum set of recommendations for reporting randomized trials and facilitates complete 
and transparent reporting, critical appraisal and interpretation.  
Specific feasibility objectives explored a) participant recruitment and retention; b) suitability 
of proposed measures to inform the selection of a primary outcome; and c) the acceptability 
of and adherence to the MOSAIC intervention and trial. Feasibility criteria are defined in 
Table 1. 
METHODS 
Study design and research governance 
A two-arm single-blinded feasibility randomised controlled trial was conducted, with a nested 
qualitative study (study registration: ISRCTN55465549). The nested qualitative study involved 
a subsample of participants of the trial and allowed the exploration of participants and a 
clinician’s experiences of receiving or delivering the intervention and participating in the trial  
between April and October 2014. This work was supported by The Dunhill Medical Trust 
[grant number: RTF09/0110].. Ethical and research governance approval was obtained from 
the UK Health Research Authority National Research Ethics Service (reference 14/NW/0089), 
and King’s College Hospital and Guy’s & St Thomas’ Hospital NHS Foundation Trusts, London, 
UK. The investigation conforms with the principles outlined in the Declaration of Helsinki.  
Participants  
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Potential participants who completed a previous observational study [16] were identified 
from vascular outpatient clinics at two NHS Hospital Foundation Trusts in London, UK, and 
screened for eligibility. Inclusion criteria were: adults aged ≥18 years with diagnosis of 
peripheral arterial disease and intermittent claudication established by a vascular clinician 
and confirmed by response to the San Diego Claudication Questionnaire [22]. Exclusion 
criteria were: asymptomatic peripheral arterial disease or rest pain established by the San 
Diego Claudication Questionnaire; revascularisation scheduled in the upcoming 4 months; 
comorbidity other than intermittent claudication self-reported as the primary limitation of 
walking; contraindication to walking; and/or inability or refusal to provide informed consent.  
Interventions 
MOSAIC is a theory-based intervention underpinned by the Common Sense Model of Illness 
Representations [13] and Theory of Planned Behaviour [14], and thus seeks to engender 
accurate and positive patient beliefs about their illness and about walking. These objectives 
were achieved through Motivational Interviewing, a collaborative and compassionate 
communication approach designed to increase personal motivation and commitment to 
behaviour change [23]. MOSAIC treatment comprised behaviour-change techniques targeting 
walking [17] (Supplementary Table 1), which were incorporated based on their 
correspondence with constructs from the theories underpinning MOSAIC and evidence for 
techniques that may be useful when targeting walking in this population [12]. MOSAIC 
treatment was delivered over 12-weeks and included two 60-minute individual face-to-face 
sessions (weeks 1 and 2) at participants’ homes, and two 20-minute booster telephone calls 
(weeks 6 and 12). After week 12, the aim was for participants to continue a programme of 
self-directed activity without supervision. A physiotherapist received 7.5 hours group training 
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in motivational interviewing (British Psychological Society accredited), 7.5 hours individual 
training in MOSAIC behaviour-change components and delivery, including role-play with 
feedback provided by the study investigators, and regular supervision and feedback via email 
and telephone to support treatment fidelity. 
The attention-control targeted dietary behaviour based on British Heart Foundation 
recommendations [24] and mirrored the mode of delivery, frequency and duration of MOSAIC 
sessions.  The attention-control was designed according to recommendations [25], in order 
to isolate the effect of walking behaviour-change techniques by balancing the duration and 
mode (i.e., face to face and telephone) of contact with the clinician between groups. 
 
Outcomes 
Outcomes were assessed at baseline and 16-week follow-up by a blinded assessor (MGH) 
during a 90 minute appointment at the School of Population Health & Environmental 
Sciences, King’s College London (London, UK). There was no treatment delivered to 
participants between the 12-week MOSAIC booster call and 16-week follow-up assessment; 
this brief gap enabled evaluation of the short-term sustained effects of MOSAIC treatment on 
outcomes.      
Sociodemographic and clinical characteristics (baseline only) were assessed by self-report and 
included: age, gender, ethnicity, smoking status, cardiovascular risk factors, medication for 
intermittent claudication, symptom duration, walking advice, past participation in supervised 
exercise therapy, and lower limb symptom classification established using the San Diego 
Claudication Questionnaire [22].  
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Two potential primary outcomes were considered: a) Walking capacity was defined as the 6 
Minute Walk Distance (metres) assessed during a standardised 6-minute walk test [26]; and 
b) Daily walking activity was measured by the mean daily step count assessed over 6 days 
using a tri-axial pedometer worn on the hip (Omron Walking Style Pro 2.0; HJ-322U-E, Omron 
Healthcare UK, Ltd., Milton Keynes, UK). Participants were given written and verbal 
instructions on how and when to wear the pedometer at their baseline and follow-up 
assessments. They were also instructed to return the pedometer after the 6 day data 
collection period in an anonymous envelope by pre-paid post or, at baseline only, via 
handover to the visiting clinician during their first treatment session. A 6 day data collection 
period was implemented to capture a combination of weekdays and weekends, and because 
this allowed practical collection of pedometers by the clinician at the 1 week MOSAIC 
treatment session. Pedometers were not provided and used as part of MOSAIC treatment. 
Patient reported outcome measures included (i) daily physical activity (Baltimore Activity 
Scale for Intermittent Claudication);[27] (ii) quality of life (Medical Outcomes Survey Short 
Form-12 version 2) [28], (iii) walking treatment beliefs (validated 23-item Theory of Planned 
Behaviour Questionnaire) [29], (iv) illness perceptions (Revised Illness Perception 
Questionnaire) [30], and (v) self-regulatory processes (validated 10-item questionnaire) [31] 
assessed at baseline and 16 weeks. 
On completion of the feasibility trial, a subsample of participants and the clinician were 
invited to an audio-recorded semi-structured interview, which followed a topic guide 
exploring the acceptability of the trial procedures and intervention received. Participants 
were purposively sampled by group allocation, ethnicity (white versus other), gender, past 
supervised exercise therapy, and median age of sample (<66 versus ≥66 years) to a target 
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sample of 12 or until data saturation was achieved. Interviews were conducted by a single 
researcher (MGH) who maintained a reflexive diary.  
Sample size and randomisation 
As this was a feasibility study, a power calculation was not conducted, and a convenience 
sample of 24 participants was targeted. Following informed consent and completion of 
baseline assessments participants were randomly allocated to either MOSAIC or an attention-
control group by simple balanced two-way randomisation.  The randomisation sequence was 
determined using an online random number generator (www.randomizer.org) to produce an 
output of 12 allocations per group and was retained by the Principal Investigator (LMB). The 
outcome assessor notified the Principal Investigator by email when a participant completed 
their baseline assessment, and the Principal Investigator then allocated the participant to the 
next consecutive group on the list.  
Analyses 
Statistical analyses were conducted in SPSS Statistics Software version 21.0 (IBM Statistics 
Inc., Armonk, NY, USA). Sociodemographic and clinical characteristics are presented as 
means ±SD for continuous variables and frequencies (%) for categorical variables. The rate 
of missing data was defined as the proportion (%) of participants with incomplete data for a 
variable at a given assessment time point. Change scores from baseline to 16-week follow-
up for 6-Minute Walk Distance and daily walking activity are reported as absolute (mean, 
SD) and relative (%) scores. To explore responsiveness of the 6-Minute Walk Distance and 
daily walking activity outcomes, the standardised response mean was calculated as the 
mean change scores divided by the SD of the change scores of the MOSAIC treatment arm.  
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Qualitative thematic content analysis of transcribed audio-recorded interviews was 
conducted using NVivo 9 (QSR International Ltd, Southport, UK) following a recommended 
protocol [32]. Themes were member-checked with participants to support resonance and 
validity. 
RESULTS 
 
Participant recruitment and retention 
Among a cohort of 94 patients, 33 could not be contacted, 15 declined to be screened, and 
46 were screened for eligibility. A target sample of 24 met the eligibility criteria and were 
enrolled onto the study (Figure 1). There were no differences between those enrolled and 
those who declined or were ineligible in terms of age (mean 66.8 versus 67.4 years) or gender 
(24% of men versus 33% of women invited).  Participants were mean 66.8 (SD=9.4, range 52-
90) years of age, and the majority were male (n=19/24) and white ethnicity (n=19/24). There 
were no substantial differences in sociodemographic or clinical characteristics at baseline 
between participants in either study group (Table 2).  
Figure 1 illustrates how the target recruitment rate of 25% was achieved from the source 
population and overall study retention at 16-week follow-up of 92% (n=22/24). All MOSAIC 
treatment group participants were retained to follow-up. One participant in the attention-
control group was undergoing cancer screening and reported this new health issue as a 
priority, so withdrew from the study. A second participant in the attention-control group 
rescheduled his follow-up appointment twice, but did not attend; no reason was given. 
Participants lost to follow-up were younger than those who completed the study (mean ±SD 
57.0 ±2.8 years versus 67.6 ±9.8 years, respectively), and were both male.  
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Suitability of proposed measures  
Missing data rates for all patient reported outcomes was <10% at each time point, and there 
were no missing data for the 6-Minute Walk Distance; therefore, feasibility criteria were 
achieved for these outcomes. 
By contrast, missing data rates were 36% (4 treatment and 4 attention-control group) and 9% 
(1 treatment and 1 attention-control group) for daily walking activity at baseline and 16 
weeks, respectively. At baseline one participant (MOSAIC) dropped and damaged the 
pedometer and two participants (one MOSAIC, one attention-control group) returned their 
pedometers 1 day early. There were no reasons given for missing baseline pedometer data 
by the remaining participants. At 16 weeks, one participant (MOSAIC) returned the 
pedometer one day early due to travel plans and one (attention-control group) returned the 
pedometer after the device’s 21-day data storage window.   
Change scores for patient reported outcomes and their associations with 6-Minute Walk 
Distance and daily walking activity are illustrated in Supplementary Table 2. The SF-12v2 
mental component summary score increased from baseline in the MOSAIC treatment group 
(mean ±SD change 2.76 ±3.56) and decreased in the attention control (mean ±SD change -
2.07 ±7.90). By contrast, the physical component summary score decreased from baseline in 
the treatment group (1.16 ±5.09) and increased in the attention-control (mean ±SD change 
6.7 ±7.0). Walking treatment beliefs (Theory of Planned Behaviour constructs), illness 
perceptions (Common Sense Model of Illness Representations constructs) and self-regulatory 
processes were positive following MOSAIC treatment compared with baseline, with the 
exception of the following Common Sense Model of Illness Representations constructs: 
identity and cyclical timeline which were unchanged, and personal control which declined. By 
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contrast patterns of change in psychosocial outcomes in the attention-control group were 
variable. The magnitudes of the associations between daily walking activity and 6-Minute 
Walk Distance were r=0.82 and r=0.59 for the treatment and attention-control, respectively. 
Associations between psychosocial constructs and walking outcomes were variable 
(Supplementary Table 2). 
6-Minute Walk Distance decreased from baseline to 16-week follow-up in participants in the 
MOSAIC group (mean -8.52 m [SD=42.29], -4.24%; n=12) and increased in the attention-
control group (mean 9.88 m [SD=42.15], 1.01%; n=10). The standardised response mean for 
6-Minute Walk Distance change scores in the MOSAIC group was 0.20 (Table 3). 
Daily walking activity increased from baseline to 16-week follow-up in the MOSIAC group 
(mean 836.91 steps/day [SD=625.83], 29.98%; n=6) and decreased in the attention-control 
group (mean -29.47 steps/day [SD=1471.43], -2.41%; n=7). The standardised response mean 
for daily walking activity change scores among the MOSAIC group was 1.34 (Table 3).  
Acceptability of and adherence to the MOSAIC intervention and trial  
Adherence to the allocated treatment was 67% (8/12) for MOSAIC and 90% (n=9/10) for the 
attention-control group. All participants completed sessions 1 and 2 delivered via home visits. 
However, 4 participants in the MOSAIC group and 2 participants in the attention-control 
group did not receive one booster telephone call because their phone was not answered at 
the scheduled appointment time and they could not be reached to reschedule the call before 
their follow-up assessment  
Narrative accounts by 12 participants (6 MOSAIC and 6 attention control group) and the 
clinician demonstrated the acceptability of the trial and treatment protocol and included 
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suggestions to improve the programme in future. Four themes were identified from the 
qualitative interviews: 1) Acceptability of the research process and protocol; 2) Acceptability 
of the treatment and attention-control interventions; 3) Perceived expectations and 
outcomes of the treatment and attention-control interventions; 4) Clinician’s role as a person 
and professional (Supplementary Table 3). There were no reported harms or potential 
adverse events. 
DISCUSSION 
This study demonstrated the feasibility and acceptability of a two-arm randomised controlled 
trial comparing a behaviour-change intervention targeting walking to an attention-control 
among people with intermittent claudication. Criteria reflecting recruitment, retention, and 
adherence to the protocol and interventions were achieved. Results additionally inform the 
selection of suitable primary and secondary outcomes and aspects of the protocol which 
could be improved. 
Study retention was high (92% overall) compared with other home-based walking 
interventions for intermittent claudication, which report rates at 12 or 24 weeks ranging from 
61–100% [12, 33]. The target recruitment rate of 25% was achieved, enabling successful 
piloting of screening procedures. Participants were drawn from a limited cohort previously 
recruited to an observational study, and so the recruitment rate and timeframe should be 
adjusted when planning a full-scale trial, taking into account known challenges to recruiting 
people with intermittent claudication to exercise trials [34, 35]. However, successful 
enrolment to the initial observational study [16] demonstrated that people with intermittent 
claudication could be identified from the vascular outpatient setting, and were interested, 
willing and available to participate in research exploring walking as treatment for their 
condition.  
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There were no missing 6-Minute Walk Distance data at any time points, suggesting this is a 
robust and feasible outcome measure. The 6-Minute Walk Distance is a valid, reliable and 
sensitive measure of functional capacity in individuals with cardiovascular diseases [36], and 
correspondent with accelerometer derived daily physical activity in people with intermittent 
claudication [37] providing a meaningful indicator of activity. In addition, our participants 
reported completing the walk test as acceptable.  
Pedometer-measured daily walking activity provided a more responsive outcome compared 
with the 6-Minute Walk Distance; this is likely because daily walking activity is a direct target 
of the intervention, reflecting behaviour change, and a more proximal outcome. However, it 
was less feasible measure due to a high proportion of missing baseline data. Interestingly, 
missing pedometer data was lower and within the feasibility criteria at follow-up assessment. 
This may be due to a learning effect, which could be addressed by further instruction and 
practice using the pedometer with the patient at baseline. Alternatively, study participation 
may have increased motivation or the likelihood of remembering to wear the pedometer.  
Another solution to improve data collection may be the use of advanced technologies, such 
as wrist-worn devices with in-built sensors, which are acceptable and validated in older 
people with cardiovascular conditions [38], and capture physical activity data beyond simple 
step-count. Alternately, there may be scope for employing pedometers or other devices as 
motivational self-monitoring tools comprising part of MOSAIC treatment rather than an 
outcome measure.  
Despite missing data, it was possible to explore the magnitude of change for both walking 
outcomes. The MOSAIC group increased daily walking activity by mean 836 steps/day, which 
corresponds with other pedometer-based interventions [39, 40]. In older adults and 
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individuals with long-term conditions, including peripheral arterial disease, 30 minutes of 
walking is approximately equivalent to 3000 steps assuming an average cadence of 100 
steps/minute [39]. Accordingly, participants in the MOSAIC group increased daily walking 
activity by mean 8.6 minutes/day, or approximately 60 minutes/week.  
By contrast, the 6-Minute Walk Distance decreased following MOSAIC, and increased in the 
attention-control group. This might be explained because the change in daily walking activity 
was below the walking guideline threshold for people with intermittent claudication (i.e., 30 
minutes on at least 3 days/week, or 90 minutes/week) [4], so was unlikely to be sufficient to 
improve 6-Minute Walk Distance. This explanation is consistent with a meta-analysis of trials 
investigating the effect of interventions using motivational interviewing, which demonstrated 
a small effect on physical activity, but not physical function in people with long-term 
conditions [41]. The challenge of achieving walking guidelines might be addressed by adding 
behaviour change techniques, such as graded tasks (e.g., gradually increasing walking goals 
until 30 minutes is achieved) and providing feedback on the outcome of walking (e.g., explicit 
feedback on symptom improvements) [17].  
Qualitative data provide insight to the potential for MOSAIC to facilitate a collaborative 
therapeutic relationship between the patient and clinician which may enable patient 
adherence to MOSAIC, satisfaction, and self-management [42].  
This study has several strengths. The feasibility success criteria included quantitative and 
qualitative data. MOSAIC was developed systematically and informed by previous findings 
and stakeholder feedback from patients with intermittent claudication and a clinician. 
Validated self-reported and objective measures of recommended outcomes for trials of 
vascular patients were explored [43], including psychosocial factors and walking which 
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provided clinically meaningful outcomes for efficacy and process evaluations. This 
intervention is consistent with recommendations for a case management approach [44], 
providing tailored and flexible care, targeting healthy lifestyle changes according to evidence-
based recommendations for management of intermittent claudication. 
Limitations include recruitment of one clinician only, which meant the feasibility of training 
and treatment delivery is not generalisable; however, in-depth qualitative data provided by 
the clinician regarding MOSAIC delivery was corroborated by experiences of patients. Our 
sample drawn from participants of a previous study might have been motivated to 
participate, increasing the risk of selection bias. Our small sample meant data were 
insufficient to inform a power calculation for a definitive trial; however, findings highlight 
feasibility of the 6-Minute Walk Distance as a primary outcome and our observational data 
including a larger sample (n=142)[16] using this measure can inform future sample size. 
Randomisation took place prior to completion of baseline pedometer data collection, which 
was carried out over the subsequent 6-day period. Therefore, this outcome was not a 
requisite for enrolment, contributing to the volume of missing data. We did not evaluate 
treadmill walking performance as a potential outcome measure based on evidence that 
corridor-based walking outcomes (such as the 6-Minute Walk Distance) are more acceptable 
to people with intermittent claudication and better reflect daily walking activity [37]. We were 
unable to evaluate mediating effects of change in theoretical constructs or behaviour-change 
techniques. 
 In conclusion, a randomised trial of a brief walking behaviour-change intervention for people 
with intermittent claudication was feasible. MOSAIC was acceptable to participants, and, by 
incorporating explicit behaviour change techniques may address the need for effective home-
based exercise programmes for people with IC [10]. This trial does not allow conclusions 
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about the efficacy of MOSAIC treatment on walking outcomes, but has informed the design 
of a definitive evaluation.  
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Figure 1. Flow of participants through the MOSAIC feasibility randomised controlled trial 
Figure 1. Flow of participants through the MOSAIC feasibility randomised controlled trial 
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Table 1. Objectives and criteria used to evaluate the feasibility of the MOSAIC trial and intervention 
Feasibility objectives Feasibility criteria Feasibility outcome 
1) to evaluate study recruitment and 
retention of participants 
1.1. A target sample of 24 participants (25% recruitment 
from initial cohort) will be achieved.  
1.1 Achieved (n=24, 25% recruitment rate) 
1.2. Study retention at 16 week follow-up will be at least 
60% (n=14/24)12,26  
1.2 Achieved (92% study retention at 16 week follow-up) 
2) to explore the suitability of proposed 
measures and identification of the 
primary outcome 
2.1. Missing data at each time point will be less than 10% 
for each outcome32.  
2.1 Achieved in part: (Missing data <10% was achieved for 6-
Minute Walk Distance and all patient reported outcome 
measures at baseline and 16-week follow-up, and for 
pedometer-based daily walking activity at 16 week-follow up. 
However, missing data rate was 36% for baseline daily walking 
activity) 
2.2 Sufficient data will be collected to explore change and 
responsiveness of objective walking outcomes.  
2.2 Achieved: (daily walking activity increased following 
treatment and decreased following attention-control and was 
more responsive compared with the 6-Minute Walk Distance, 
whereas the opposite pattern was found for 6-Minute Walk 
Distance, which was a less responsive outcome.) 
3) to explore adherence to and 
acceptability of the MOSAIC interventions 
and trial protocol  
3.1 At least 60% (n=14/24) of participants will complete 
all treatment and attention-control sessions.  
3.1 Achieved (71% adherence to protocolled sessions) 
3.2 Participants and the clinician will report positive 
experiences of MOSAIC treatment and the study protocol. 
3.2 Achieved (narrative reports were positive and 
constructive) 
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Table 2. Baseline sociodemographic and clinical characteristics of participants in the MOSAIC 
feasibility trial 
Variable Treatment, n (%) Attention-control, n (%) 
Age 66.3 ±8.8a 67.1 ±11.2a 
Body mass index, kg/m2 28.6 ±5.0a 26.5 ±5.0a 
Male gender 9 (75.0) 10 (83.0) 
Married 6 (50.0) 7 (58.3) 
White ethnicity 11 (91.6) 9 (75.0) 
Current smoker 4 (33.3) 6 (50.0) 
Cardiovascular risk factors   
Diabetes 3 (25.0) 4 (33.3) 
Hypertension 10 (83.3) 8 (66.7) 
Dyslipidaemia 8 (66.7) 5 (38.5) 
Cardiovascular disease 8 (66.7) 4 (33.3) 
Pharmacological pain management 2 (16.6) 1 (8.3) 
Walking advice 6 (50.0) 7 (58.3) 
Past supervised exercise therapy 5 (38.5) 3 (25.0) 
Past revascularisation 1 (8.3) 2 (16.6) 
Lower-limb symptom classification   
Atypical intermittent claudication 7 (58.3) 6 (50.0) 
Classic intermittent claudication 5 (38.5) 6 (50.0) 
Duration of intermittent claudication <1 year 1 (8.3) 0 
n=24 (12 per group). aData are mean ±SD.  
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Table 3. Baseline, 16 week follow-up, and change scores for 6-Minute Walk Distance and daily 
walking activity  
Outcome Treatment, mean ±SD Attention-control, mean 
±SD 
6-Minute Walk Distance   
Participants 12a 10a 
Baseline, metres 390.44 ±101.81 378.05 ±157.06 
Follow-up, metres 381.92 ±113.51 387.93 ±161.84 
Change, metres -8.52 ±42.29 9.88 ±42.15 
Change, % -4.23 ±12.56 1.01 ±13.346 
Standardised response mean 0.20 Not applicable 
Daily walking activity    
Participants 6a 7a 
Baseline, steps/day 2247.02 ±1652.05 4343.28 ±3098.87 
Follow-up, steps/day 3083.94 ±1882.59 4313.80 ±1113.45 
Change, steps/day 836.91 ±625.83 -29.47 ±1471.43 
Change, % 29.98 ±17.57 -2.41 ±40.81 
Standardised response mean 1.34 Not applicable 
aData are the valid numbers of participants. 
 
 
 
 
